Neoton (Phosphocreatine Sodium)

Phosphocreatine sodium, the active ingredient in Neoton, is a creatine phosphate presented as a solution for injection for intravenous use. It provides exogenous phosphocreatine to support myocardial energy metabolism in patients with ischemic heart disease, heart failure, and during cardiac surgery. GNH USA supplies Neoton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Neoton acts on cardiac energy metabolism and is employed in several cardioprotective contexts.

Myocardial ischemia: improves myocardial ATP regeneration during reduced blood flow. Heart failure: supports cardiac contractility by enhancing cellular energy stores. Cardiac surgery support: maintains myocardial energy balance during operative stress.

Adverse reactions may occur with intravenous administration of phosphocreatine sodium solutions.

Common Side Effects: - Injection site pain or erythema. - Mild hypotension or transient dizziness. - Nausea or mild gastrointestinal discomfort. - Headache. - Transient flushing.

Serious or Rare Side Effects: - Severe hypotension or cardiovascular collapse. - Cardiac arrhythmias. - Anaphylactic or severe allergic reactions. - Hyperkalemia. - Worsening of myocardial infarction symptoms.

Neoton should be used with careful clinical monitoring.

Assess cardiac function: obtain baseline ECG and cardiac biomarkers before infusion. Monitor hemodynamics: observe blood pressure and heart rate during and after administration. Review electrolyte status: correct significant imbalances prior to use. Avoid in uncontrolled arrhythmias: defer use if severe rhythm disturbances are present. Pregnancy and lactation: use only if potential benefit justifies potential risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions require attention when prescribing Neoton.

Major Interactions (Avoid): - Concurrent high‑dose catecholamines: may increase risk of life‑threatening arrhythmias. - Co‑administration with other ATP‑modulating agents: can cause metabolic instability.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and volume status. - Beta‑blockers: watch for additive hypotensive effects. - ACE inhibitors or ARBs: assess renal function and blood pressure. - Anticoagulants: observe for bleeding tendencies due to hemodynamic changes.